Incorrect Use of Process Validation Tools Led to FDA Warning Letters
This article was originally published in The Gold Sheet
Executive Summary
Manufacturers have been learning the hard way not to use fancy statistical tools for process validation without really understanding them. Inappropriate sampling plans, Cpk analyses, defect/complaint rate analyses and other such failures recently triggered FDA warning letters.